Cytarabine
- Generic Name
- Cytarabine
- Brand Names
- Cytosar, Vyxeos
- Drug Type
- Small Molecule
- Chemical Formula
- C9H13N3O5
- CAS Number
- 147-94-4
- Unique Ingredient Identifier
- 04079A1RDZ
- Background
A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra P...
- Indication
For the treatment of acute non-lymphocytic leukemia, acute lymphocytic leukemia and blast phase of chronic myelocytic leukemia.
...
- Associated Conditions
- Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia, Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Acute Promyelocytic Leukemia, Meningeal leukemia, Metastatic Malignant Neoplasm to the Leptomeninges, Non-Hodgkin's Lymphoma (NHL), Treatment-Related Acute Myeloid Leukemia, Blast phase Chronic myeloid leukemia
- Associated Therapies
- -
A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Azacitidine and Venetoclax, in Patients With Higher-risk Myeloproliferative Chronic Myelomonocytic Leukemia or Higher-risk Myelodysplastic Syndromes With Excess Blasts
- Conditions
- Interventions
- First Posted Date
- 2022-05-06
- Last Posted Date
- 2024-06-04
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 60
- Registration Number
- NCT05365035
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Venetoclax Plus Intensive Chemotherapy in AML and Advanced MDS
- Conditions
- Interventions
- First Posted Date
- 2022-04-22
- Last Posted Date
- 2024-08-02
- Lead Sponsor
- Ioannis Mantzaris
- Target Recruit Count
- 99
- Registration Number
- NCT05342584
- Locations
- 🇺🇸
Montefiore Einstein Cancer Center, Bronx, New York, United States
GM-CLAG in Relapsed/Refractory FLT3-mutated AML
- Conditions
- Interventions
- First Posted Date
- 2022-04-15
- Last Posted Date
- 2023-04-25
- Lead Sponsor
- Ayman H Qasrawi
- Registration Number
- NCT05330377
- Locations
- 🇺🇸
University of Kentucky, Lexington, Kentucky, United States
A Study of the Drug IMGN632 in Children With Leukemia That Has Come Back After Treatment or is Difficult to Treat
- Conditions
- Recurrent Acute Myeloid LeukemiaRecurrent Mixed Phenotype Acute LeukemiaRefractory T Acute Lymphoblastic LeukemiaRefractory Acute Myeloid LeukemiaRecurrent T Acute Lymphoblastic LeukemiaRecurrent B Acute Lymphoblastic LeukemiaRefractory B Acute Lymphoblastic LeukemiaRefractory Mixed Phenotype Acute Leukemia
- Interventions
- First Posted Date
- 2022-04-11
- Last Posted Date
- 2023-09-01
- Lead Sponsor
- Children's Oncology Group
- Registration Number
- NCT05320380
Study of Liposomal Annamycin in Combination with Cytarabine for the Treatment of Subjects with Acute Myeloid Leukemia (AML)
- Conditions
- Interventions
- First Posted Date
- 2022-04-08
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Moleculin Biotech, Inc.
- Target Recruit Count
- 63
- Registration Number
- NCT05319587
- Locations
- 🇮🇹
Istituto Scientifico Romagolo per lo studio dei umori "Dino Amadori" (IRST) - IRCCS, Meldola, FC, Italy
🇵🇱Uniwersytecki Szpital Kliniczny Klinika Hematologii Nowotworow, Wrocław, Dolnośląskie województwo, Poland
🇮🇹IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy
Venetoclax to Augment Epigenetic Modification and Chemotherapy
- First Posted Date
- 2022-04-07
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Medical College of Wisconsin
- Target Recruit Count
- 40
- Registration Number
- NCT05317403
- Locations
- 🇺🇸
Children's Wisconsin, Milwaukee, Wisconsin, United States
Treateament of Newly Diagnosed Acute Monocytic Leukemia in Children
- Conditions
- Interventions
- First Posted Date
- 2022-04-06
- Last Posted Date
- 2023-07-27
- Target Recruit Count
- 43
- Registration Number
- NCT05313958
- Locations
- 🇨🇳
Guangzhou First People's Hospital, Guangzhou, Guangdong, China
🇨🇳The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China
🇨🇳Maternal and Child Health Hospital of Foshan, Foshan, Guangdong, China
Testing the Combination of Inotuzumab Ozogamicin and Lower Dose Chemotherapy Compared to Usual Chemotherapy for Adults With B-Cell Acute Lymphoblastic Leukemia or B-Cell Lymphoblastic Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2022-03-31
- Last Posted Date
- 2024-08-02
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 66
- Registration Number
- NCT05303792
- Locations
- 🇺🇸
NorthShore University HealthSystem-Evanston Hospital, Evanston, Illinois, United States
🇺🇸Marshfield Medical Center - Weston, Weston, Wisconsin, United States
🇺🇸Marshfield Medical Center-River Region at Stevens Point, Stevens Point, Wisconsin, United States
Venetoclax Basket Trial for High Risk Hematologic Malignancies
- Conditions
- Myelodysplastic Syndromes, SecondaryMyelodysplastic Syndromes, Previously TreatedTreatment-Related Acute Myeloid LeukemiaTherapy-Related Myelodysplastic SyndromeAcute Lymphoblastic Leukemia With Failed RemissionMyelodysplastic Syndromes, de NovoLymphoblastic Lymphoma, in RelapseAcute Leukemia of Ambiguous Lineage in RelapseLymphoblastic Lymphoma, RefractoryAcute Leukemia of Ambiguous Lineage
- Interventions
- First Posted Date
- 2022-03-23
- Last Posted Date
- 2024-04-02
- Lead Sponsor
- Andrew E. Place, MD
- Target Recruit Count
- 92
- Registration Number
- NCT05292664
- Locations
- 🇺🇸
University of California San Francisco-Benioff Children's Hospital, San Francisco, California, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Loncastuximab Tesirine in Combination With Chemotherapy Prior to Stem Cell Transplant for the Treatment of Recurrent or Refractory Diffuse Large B-Cell Lymphoma
- Conditions
- Recurrent Diffuse Large B-Cell LymphomaRecurrent Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedRecurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 RearrangementsRefractory Transformed Follicular Lymphoma to Diffuse Large B-Cell LymphomaRecurrent Primary Mediastinal (Thymic) Large B-Cell LymphomaRecurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell LymphomaRefractory Diffuse Large B-Cell LymphomaRefractory Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedRefractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 RearrangementsRefractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma
- Interventions
- First Posted Date
- 2022-02-08
- Last Posted Date
- 2023-01-13
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Registration Number
- NCT05228249
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.